# A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)

> **NCT07108816** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Resectable Stage II-IIIB NSCLC

## Interventions

- **DRUG:** Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab

## Key facts

- **NCT ID:** NCT07108816
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-08-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07108816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07108816, "A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07108816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*